{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:38:44Z","timestamp":1786714724365,"version":"build-2736575974"},"reference-count":23,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transfusion Medicine"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Daratumumab is a monoclonal antibody therapy used to treat multiple myeloma. It has introduced challenges for blood transfusion laboratories to provide safe red cells for transfusion due to the cross\u2010reactivity of daratumumab with red cell surface antigens on antibody screening cells, resulting in panreactivity and preventing the exclusion of alloantibodies. NHS Lothian transfusion protocol for patients on daratumumab involves pre\u2010daratumumab extended patient phenotyping of significant RBC antigens and transfusion of RhD (CcEe) and K phenotype matched Red Cell Concentrate (RCC) without performing any pre\u2010transfusion antibody screening.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>To determine alloimmunisation rates following the current protocol the laboratory information management system (LIMS) was interrogated to determine if patients previously on daratumumab had developed antibodies in response to transfused RCCs. Grifols sCD38 was used to neutralise daratumumab in transfused patients. sCD38 was used to (1) assess alloimmunisation rates in patients on treatment (2) assess how it could be applied in a routine pre transfusion testing protocol.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Since 2018, 185 patients started daratumumab therapy in Lothian. There was a record of RCC transfusion in 102 patients. From the LIMS, negative antibody screens were recorded in 21 patients post\u2010daratumumab treatment. No alloimmunisation was detected from 34 transfused patients still on daratumumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Low alloimmunisation suggests NHS Lothian protocol for transfusion of daratumumab patients is safe. Extended phenotyping of patients pre\u2010treatment may be extensive and unnecessary due to the low alloimmunisation rate. Implementation of sCD38 reagent into pre\u2010transfusion testing can reduce extensive pre\u2010treatment testing and improve the safety of transfusion by exclusion of alloantibodies in daratumumab patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/tme.70046","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:53:25Z","timestamp":1764809605000},"page":"354-359","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Determining a safe pre\u2010transfusion protocol for multiple myeloma patients on anti\u2010\n                    <scp>CD38<\/scp>\n                    treatment"],"prefix":"10.1111","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-5310-0393","authenticated-orcid":false,"given":"Amanda","family":"Nicolson","sequence":"first","affiliation":[{"name":"Blood Transfusion, Blood Science Laboratories Western General Hospital  Edinburgh UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Falconer","sequence":"additional","affiliation":[{"name":"Blood Transfusion, Blood Science Laboratories Western General Hospital  Edinburgh UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"GoodingS.Getting precise over multiple myeloma.2024Accessed 17 February 2024.https:\/\/news.cancerresearchuk.org\/2024\/01\/08\/getting-precise-over-multiple-myeloma\/."},{"key":"e_1_2_10_3_1","unstructured":"International Myeloma Foundation.What Is Multiple Myeloma?2024Accessed: 23 June 2024.https:\/\/www.myeloma.org\/what-is-multiple-myeloma."},{"key":"e_1_2_10_4_1","unstructured":"National Cancer Institute.Plasma cell neoplasms (including multiple myeloma) treatment (PDQ\u00ae)\u2010patient version.2023Accessed 21 February 2024.https:\/\/www.cancer.gov\/types\/myeloma\/patient\/myeloma-treatment-pdq."},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/tme.12808"},{"key":"e_1_2_10_6_1","unstructured":"Grifols.Grifols sCD38: Cutting\u2010edge technology to overcome lab challenges.2023Accessed 11 March 2024.https:\/\/www.diagnostic.grifols.com\/documents\/4804410\/4807854\/Brochure_Grifols_sCD381.pdf\/268182d2\u2010b29c\u2010b550\u20106d33\u2010ade04acf4933?t=1698793524337."},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/imj.13707"},{"key":"e_1_2_10_8_1","unstructured":"JPAC.13.3: Pre\u2010transfusion testing.2023Accessed 18 May 2024.https:\/\/www.transfusionguidelines.org\/red-book\/chapter-13-patient-testing-red-cell-immunohaematology\/13-3-pre-transfusion-testing."},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2024.103873"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S213510"},{"key":"e_1_2_10_11_1","unstructured":"Engstr\u00f6mC ScherrerE FalconerJ et al.A multicenter evaluation of soluble CD38 plasma pre\u2010treatment to neutralize anti\u2010CD38 pan\u2010reactivity with RBCs.34th Regional ISBT Congress in Cape Town\u2010 Cape Town (South Africa).2023."},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102018\u201099\u2010115848"},{"key":"e_1_2_10_13_1","first-page":"624","article-title":"Increased incidence of red blood cell alloantibodies in myelodysplastic syndrome","volume":"17","author":"Rozovski U","year":"2015","journal-title":"IMAJ"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.17945\/kjbt.2022.33.1.14"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.5772\/intechopen.1003885"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/voxs.12360"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12288-024-01763-5"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12864"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.16425"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.09.002"},{"key":"e_1_2_10_21_1","unstructured":"KoscheRK ScherrerE ZorbasA et al.sCD38: an alternative to resolve Daratumumab\u2010induced interference with blood compatibility testing. Swisstransfusion Rorschach.2023."},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.9734\/ibrr\/2024\/v15i3343"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.23736\/S1825\u2010859X.24.00242\u20101"},{"issue":"1","key":"e_1_2_10_24_1","article-title":"Impact of alloimmunisation in patients with sickle cell disease","volume":"138","author":"Debnath D","year":"2021","journal-title":"Blood Transfus"}],"container-title":["Transfusion Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tme.70046","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/tme.70046","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tme.70046","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:14:36Z","timestamp":1786713276000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tme.70046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1111\/tme.70046"],"URL":"https:\/\/doi.org\/10.1111\/tme.70046","archive":["Portico"],"relation":{},"ISSN":["0958-7578","1365-3148"],"issn-type":[{"value":"0958-7578","type":"print"},{"value":"1365-3148","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]},"assertion":[{"value":"2025-06-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}